期刊
MOLECULAR THERAPY
卷 16, 期 7, 页码 1189-1199出版社
CELL PRESS
DOI: 10.1038/mt.2008.103
关键词
-
资金
- NIAMS NIH HHS [R37 AR040864, R37 AR040864-19] Funding Source: Medline
- NIA NIH HHS [P01 AG015434, P01 AG015434-100001] Funding Source: Medline
- NINDS NIH HHS [P01 NS046788, P01 NS046788-050001] Funding Source: Medline
Recombinant adeno-associated virus (rAAV) holds promise as a gene therapy vector for a multitude of genetic disorders such as hemophilia, cystic fibrosis, and the muscular dystrophies. Given the variety of applications and tissue types toward which these vectors may be targeted, an understanding of rAAV transduction is crucial for the effective application of therapy. rAAV transduction mechanisms have been the subject of much study, resulting in a body of knowledge relating to events from virus-cell attachment through to vector genome conformation in the target cell nucleus. Instead of utilizing one mechanism in each phase of vector transduction, rAAV appears to employ multiple possible pathways toward transgene expression, in part dependent on rAAV serotype, dose, and target cell type. Once inside the nucleus, the rAAV genome exists in a predominantly episomal form; therefore, nondividing cells tend to be most stably transduced. However, rAAV has a low frequency of integration into the host cell genome, often in or near genes, and can be associated with host genome mutations. This review describes the current understanding of the mechanisms and rate-limiting steps involved in rAAV transduction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据